Ideas – Page 133

February 15, 2019

Published by admin_auro at February 15, 2019

Categories

Empagliflozin (EMBA)-based therapy for Cardiac repair and myocardial infarction: Empagliflozin (EMBA) (trade name: Jardiance), a sodium-glucose cotransporter 2 inhibitor used in the treatment of TIIDM, increases Agrin expression, activates Yap and ERK-mediated signaling, replaces scar tissue with functional cardiomyocytes, and promotes cardiomyocyte regeneration and repair after myocardial infarction, via up-regulation of its target gene, 15/February/2019, 7.37 am

Introduction: What they say: A recent study from Department of Molecular Cell Biology, Weizmann Institute of Science, Rehovot 76100, Israel; Department of Biomedical Engineering, Duke University, […]

February 15, 2019

Published by admin_auro at February 15, 2019

Categories

Cancer
Ideas

Combinatorial therapy for Notch1-overexpressing Human cancers: A therapeutic mix encompassing Metformin and Navitoclax/ABT-263 (MAN) inhibits the expression of Notch1, and adhesion molecule VCAM1, suppresses neutrophil infiltration and tumor cell adhesion to endothelium and prevents Notch1-driven metastasis via upregulation of its target gene, 15/February/2019, 7.26 am

Introduction: What they say: A study from the Vascular Signaling and Cancer, German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany; Vascular Biology, CBTM, Medical Faculty Mannheim, […]

February 15, 2019

Published by admin_auro at February 15, 2019

Categories

Ribonucleic acid-based therapy for aging-associated diseases and Lifespan extension: LncRNA ANSR inhibits the interaction of DBC1 with PARP1, increases the PARP1 activity, promotes DNA repair, augments tolerance against radiation, cancer, and aging, via down-regulation of its target gene, 15/February/2019, 7.16 am

Introduction: What they say A study from Department of Genetics, Paul F. Glenn Center for the Biology of Aging, Harvard Medical School, Boston, MA, USA; and […]

February 15, 2019

Published by admin_auro at February 15, 2019

Categories

Dapagliflozin-based therapy for Cardiac repair and myocardial infarction: Dapagliflozin (brand name: Forxiga, Farxiga), a sodium glucose cotransporter inhibitor used in the treatment of TIIDM, increases Agrin expression, activates Yap and ERK-mediated signaling, replaces scar tissue with functional cardiomyocytes, and promotes cardiomyocyte regeneration and repair after myocardial infarction, via up-regulation of its target gene, 15/February/2019, 6.33 am

Introduction: What they say: A recent study from Department of Molecular Cell Biology, Weizmann Institute of Science, Rehovot 76100, Israel; Department of Biomedical Engineering, Duke University, […]